Literature DB >> 16530743

Generation of CD133+ cells from CD133- peripheral blood mononuclear cells and their properties.

Erik J Suuronen1, Serena Wong, Varun Kapila, Geeta Waghray, Stewart C Whitman, Thierry G Mesana, Marc Ruel.   

Abstract

OBJECTIVE: CD133 may be the most specific marker of endothelial progenitor cells (EPCs), which are thought to be largely confined to the bone marrow milieu. This study reports on the phenotypic characterization and functional analysis of human CD133+ cells and their generation from cells in the peripheral circulation.
METHODS: Adult human CD133+ and CD133- cells were isolated from peripheral blood mononuclear cells, and the generation of CD133+ cells in culture was attempted using different culture combinations. The phenotypic, migratory, adhesive, and angiogenic properties of the native and generated populations were investigated.
RESULTS: In adherent and in suspension culture systems, CD133+ cells also expressing CD34 and VEGFR-2 were successfully derived from a previously CD133- population. The migratory potential of CD133+ cells was enhanced by the presence of the CD133- cells. Also, the CD133+ cells derived from the CD133- cells demonstrated improved adhesion to extracellular matrix and endothelial monolayer substrates, and their contribution to in vitro angiogenesis was enhanced compared to freshly isolated CD133+ cells.
CONCLUSIONS: These results demonstrate a source of blood CD133+ cells other than direct mobilization from the bone marrow. Cellular interaction was observed between fractions, with CD133+ cells showing better in vitro function in the presence of CD133- cells. These findings provide a novel source for CD133+ cells and a rationale for the investigation of angiogenic cell recruitment or delivery strategies involving more than one cell type at ischemic sites.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16530743     DOI: 10.1016/j.cardiores.2006.01.014

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  7 in total

1.  A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma.

Authors:  Nate N Waldron; Sanford H Barsky; Phillip R Dougherty; Daniel A Vallera
Journal:  Target Oncol       Date:  2013-07-31       Impact factor: 4.493

2.  Endothelial progenitor cells homing to the orthotopic implanted liver tumor of nude mice.

Authors:  Zhi Zhu; Gang Chen; Xingrui Li; Qian Yin; Zhifang Yang; Jilin Yi
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-10-18

3.  Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer.

Authors:  Nate N Waldron; Dan S Kaufman; Seunguk Oh; Zintis Inde; Melinda K Hexum; John R Ohlfest; Daniel A Vallera
Journal:  Mol Cancer Ther       Date:  2011-08-23       Impact factor: 6.009

4.  Biological characteristics of human-urine-derived stem cells: potential for cell-based therapy in neurology.

Authors:  Jun-Jie Guan; Xin Niu; Fei-Xiang Gong; Bin Hu; Shang-Chun Guo; Yuan-Lei Lou; Chang-Qing Zhang; Zhi-Feng Deng; Yang Wang
Journal:  Tissue Eng Part A       Date:  2014-05-19       Impact factor: 4.080

Review 5.  CD133, Selectively Targeting the Root of Cancer.

Authors:  Jörg U Schmohl; Daniel A Vallera
Journal:  Toxins (Basel)       Date:  2016-05-28       Impact factor: 4.546

6.  Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.

Authors:  Jörg U Schmohl; Martin Felices; Felix Oh; Alexander J Lenvik; Aaron M Lebeau; Jayanth Panyam; Jeffrey S Miller; Daniel A Vallera
Journal:  Cancer Res Treat       Date:  2017-02-20       Impact factor: 4.679

7.  Absence of a relationship between immunophenotypic and colony enumeration analysis of endothelial progenitor cells in clinical haematopoietic cell sources.

Authors:  Olga Tura; G Robin Barclay; Huw Roddie; John Davies; Marc L Turner
Journal:  J Transl Med       Date:  2007-07-18       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.